Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.’s business practices, including whether it has made it too hard for customers to cancel subscriptions, ...

After Bloomberg reported, citing people familiar with the probe, that the Federal Trade Commission has been investigating ...

Telehealth company Hims & Hers Health’s (HIMS) business practices have been under investigation by the U.S. Federal Trade Commission (FTC) for over a year, Bloomberg reported. Following the news, HIMS ...

Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock dropped 2.6% on Friday following reports that the Federal Trade Commission has been investigating the telehealth company's business practices for ...

Allen Lutz has given his Buy rating due to a combination of factors including the strong brand equity of Hims & Hers Health and the strategic appointment of a new board member with significant ...

The latest health news highlights Britain's stance on the bioethanol industry, Berkshire Hathaway's investment moves, the FTC's probe into Hims & Hers, Scorpion Capital's position on Soleno ...